PCSK9 and cardiovascular disorder: The identification of PCSK9 as a target for lipid-lowering drugs occurred as a result of the recognition that loss-of-function mutations of PCSK9 resulted in reduced circulating concentrations of LDL-C and a lower risk of cardiovascular disease [28].